NCT07570316ClinicalTrials.gov
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs
En bref
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is…
Phase 3230 participants recherchés35 sites3 pays
Catégories
Enregistré dans 1 registre
- ClinicalTrials.govNCT07570316Ouvrir cette fiche sur ClinicalTrials.govSynchronisé il y a 2 semaines
Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.
Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.
Cette étude vous intéresse ?
Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2026-05-06; recorded start 2026-06-10
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Present: Uses blinding (masking)A masking level is recorded in the record
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 87 other studies in this databaseCounted from the lead sponsor named in the record (argenx)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 2 conditions.
- Lead sponsor type recorded as: industry.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding20/20
Quadruple-blind
- Control arm13/15
Placebo / sham control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type3/10
Surrogate or intermediate endpoint (conservative default)
- Multi-centre8/8
Multi-centre: 18 sites
- Data monitoring committee0/7
Data monitoring committee not stated in the record
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A medium-sized study, international in scope: 230 participants (target), run at 35 sites, across 3 countries.
How this score is built
- Enrolment23/40
230 participants (target)
- Site count15/25
18 sites
- Country count7/15
2 countries
- Planned duration9/10
Planned over about 47 months
- Sponsor scale7/10
argenx has led 83 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Résumé
The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy
Affections
- Graves' Disease
- Graves Disease
Éligibilité
| Sexe | Tous |
|---|---|
| Âges | 18 Years – Aucun maximum |
| Volontaires sains | Non |
Éligibilité telle qu'elle figure dans le registre
Éligibilité en énoncés simples
Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.
Conception de l'étude
| Type d'étude | Interventionnelle |
|---|---|
| Phase | Phase 3 |
| Répartition | Randomisée |
| Modèle d'intervention | PARALLEL |
| Objectif principal | TREATMENT |
| Insu | QUADRUPLE (4) |
| Recrutement | 230 participants recherchés |
Promoteur et collaborateurs
- argenx Promoteur
Groupes et interventions
- Part A - efgartigimod PH20 SC PFSEXPERIMENTAL
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
- Part A - placebo PH20 SC PFSPLACEBO_COMPARATOR
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.
- Part B - efgartigimod PH20 SC PFSEXPERIMENTAL
Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
- Part B - placebo PH20 SC PFSEXPERIMENTAL
Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.
- Part C - efgartigimod PH20 SC PFSEXPERIMENTAL
Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period
Interventions
- Produit biologique Efgartigimod PH20 SC
Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)
- Autre Placebo PH20 SC
Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)
Critères de jugement
Critère de jugement principal
Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A
Free triiodothyronine: \[fT3\]; free thyroxine: \[fT4\]; ATDs: antithyroid drugs
Délai Up to 24 weeks (part A)
Critère de jugement secondaire
Time to becoming euthyroid off ATDs in part A
ATDs: antithyroid drugs
Délai Up to 24 weeks (part A)
Critère de jugement secondaire
Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A
MMI: methimazole (also known as thiamazole); CBZ: carbimazole.
Délai Up to 24 weeks (part A)
Critère de jugement secondaire
Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A
ULN : upper limit of normal; ATDs: antithyroid drugs.
Délai Up to 24 weeks (part A)
Critère de jugement secondaire
Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A
TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs.
Délai Up to 24 weeks (part A)
Critère de jugement secondaire
Time to becoming euthyroid off ATDs and TRAb seronegative
ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies.
Délai Up to 24 weeks (part A) + up to 135 weeks
Critère de jugement secondaire
Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)
ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole.
Délai Up to 24 weeks (Part A)
Critère de jugement secondaire
Time to becoming euthyroid
Délai Up to 24 weeks (part A) + up to 135 weeks
Critère de jugement secondaire
Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)
TSH: thyroid-stimulating hormone; LLN: lower limit of normal.
Délai Up to 24 weeks (part A)
Critère de jugement secondaire
Percentage of participants who remain euthyroid without ATDs
ATDs: antithyroid drug
Délai Up to 74 weeks (part B)
Critère de jugement secondaire
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months
ATDs: antithyroid drug
Délai Up to 74 weeks (part B) + up to 135 weeks
Critère de jugement secondaire
Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS
ATDs: antithyroid drug
Délai Up to 72 weeks (part C)
Critère de jugement secondaire
Incidence of AEs and SAEs
AEs: adverse events ; SAEs: serious adverse events.
Délai Up to 135 weeks
Critère de jugement secondaire
Change in ThyPRO-39 over time
The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status.
Délai Up to 135 weeks
Critère de jugement secondaire
Change in PROMIS-PF10a over time
The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function.
Délai Up to 135 weeks
Critère de jugement secondaire
Efgartigimod serum concentrations over time
Délai Up to 24 weeks (part A) + 72 weeks (part C)
Critère de jugement secondaire
Percentage change from baseline in total IgG levels in serum over time
IgG: immunoglobulin G
Délai Up to 98 weeks
Critère de jugement secondaire
Percentage change from baseline in TRAb serum levels over time
TRAb: anti-TSHR autoantibodies.
Délai Up to 135 weeks
Critère de jugement secondaire
Incidence of ADA against efgartigimod in serum
ADA: antidrug antibody(ies)
Délai Up to 24 weeks (part A) + up to 135 weeks
Critère de jugement secondaire
Incidence of antibodies against rHuPH20 in plasma
rHuPH20: recombinant human hyaluronidase PH20
Délai Up to 24 weeks (part A) + Up to 135 weeks
Critère de jugement secondaire
Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma
NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20.
Délai Up to 24 weeks (part A) + up to 135 weeks
Dates
| Date de début | 10 juin 2026 (réelle) |
|---|---|
| Achèvement principal | 1 juin 2028 (estimée) |
| Achèvement | 1 mai 2030 (estimée) |
| Première publication | 6 mai 2026 (réelle) |
| Dernière mise à jour | 3 novembre 2026 |
| Résultats publiés | Non précisé dans la fiche du registre |
| Statut vérifié pour la dernière fois | septembre 2026 |
Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.
Lieux
35 sites sont en recrutement
Georgia
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| LLC American Hospital Network | Tbilisi | En recrutement | |
| In Vitro Fertilization Center LLC | Tbilisi | En recrutement | |
| LLC Todua Clinic | Tbilisi | En recrutement | |
| New Hospitals | Tbilisi | En recrutement | |
| LTD Israeli-Georgian Medical Research Clinic Healthycore | Tbilisi | En recrutement |
United Kingdom
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust) | Gateshead | Tyne and Wear | En recrutement |
United States
| Établissement | Ville | État ou région | Statut |
|---|---|---|---|
| Albany Medical College Community Endocrinology | Albany | New York | En recrutement |
| University of Michigan | Ann Arbor | Michigan | En recrutement |
| Asheville Clinical Research | Asheville | North Carolina | En recrutement |
| Profound Research LLC at Tri-City Primary Care | Carlsbad | California | En recrutement |
| Research Institute of Dallas | Dallas | Texas | En recrutement |
| Metro Detroit Endocrinology Center | Dearborn | Michigan | En recrutement |
| Frontier Medical Center - Academy of Diabetes Thyroid and Endocrine | El Paso | Texas | En recrutement |
| Profound Research | Farmington Hills | Michigan | En recrutement |
| Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park Location | Fleming Island | Florida | En recrutement |
| The Center for Diabetes and Endocrine Care | Fort Lauderdale | Florida | En recrutement |
| Juno Research | Houston | Texas | En recrutement |
| Clinic of Endocrinology | Houston | Texas | En recrutement |
| Tekton Research Irving | Irving | Texas | En recrutement |
| University of Florida Jacksonville College of Medicine | Jacksonville | Florida | En recrutement |
| Truman Medical Center | Kansas City | Missouri | En recrutement |
| Ilumina Medical Research LLC | Kissimmee | Florida | En recrutement |
| Johnson County Clin-Trials, Inc. | Lenexa | Kansas | En recrutement |
| Biopharma Informatic, LLC | McAllen | Texas | En recrutement |
| Tekton Research - McKinney | McKinney | Texas | En recrutement |
| Southern Endocrinology Associates PA | Mesquite | Texas | En recrutement |
| Oceane 7 Medical & Research Center, Inc | Miami | Florida | En recrutement |
| Endocrine Associates of West Village PC | New York | New York | En recrutement |
| Diabetes Associates Medical Group | Orange | California | En recrutement |
| Havana Research Institute LLC. | Pasadena | California | En recrutement |
| Pasadena Clinical Trials | Pasadena | California | En recrutement |
| Wake Internal Medicine Consultants | Raleigh | North Carolina | En recrutement |
| San Jose Clinical Trials | San Jose | California | En recrutement |
| Consano Clinical Research | Shavano Park | Texas | En recrutement |
| Alliance for Multispecialty Research, LLC | Wichita | Kansas | En recrutement |
Documents de l'étude
Aucun document n'est lié dans cette fiche du registre.
Évolution au fil du temps
- 3 novembre 2026
Site ajouté
3 sites added (35 total)
3235
- 16 octobre 2026
Site ajouté
6 sites added (32 total)
2632
- 22 septembre 2026
Site ajouté
3 sites added (26 total)
2326
- 17 septembre 2026
Site ajouté
1 site added (23 total)
2223
- 12 août 2026
Site ajouté
4 sites added (22 total)
1822